Identification of prognostic nutritional index as a reliable prognostic indicator for advanced lung cancer patients receiving immune checkpoint inhibitors
X Yan, J Wang, J Mao, Y Wang, X Wang, M Yang… - Frontiers in …, 2023 - frontiersin.org
Background Prognostic nutritional index (PNI) has been identified as a reliable prognostic
factor for cancer adjuvant therapy. However, its prognostic value in lung cancer patients …
factor for cancer adjuvant therapy. However, its prognostic value in lung cancer patients …
[HTML][HTML] Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy …
P Trinkner, S Günther, I Monsef, E Kerschbaum… - European Journal of …, 2023 - Elsevier
Background Imbalanced body composition is mechanistically connected to dysregulated
immune activities. Whether overweight/obesity or sarcopenia has an impact on treatment …
immune activities. Whether overweight/obesity or sarcopenia has an impact on treatment …
Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy
C Minichsdorfer, A Gleiss, MB Aretin… - Annals of …, 2022 - Taylor & Francis
Background Immune checkpoint inhibitors (ICI) are regarded as a standard of care in
multiple malignancies. We hypothesized that serum parameters are of prognostic value in …
multiple malignancies. We hypothesized that serum parameters are of prognostic value in …
Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis
LL Li, CF Yu, HT Xie, Z Chen, BH Jia, FY Xie… - Cancer …, 2023 - Wiley Online Library
Objective The aim of this meta‐analysis was to summarize the available results of
immunotherapy predictors for small cell lung cancer (SCLC) and to provide evidence‐based …
immunotherapy predictors for small cell lung cancer (SCLC) and to provide evidence‐based …
Impact of BMI on the survival outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis
T Zhang, S Li, J Chang, Y Qin, C Li - BMC cancer, 2023 - Springer
Objectives ICIs have become the standard treatment for advanced NSCLC patients.
Currently, PD-L1 is the most widely useful biomarker to predict ICI efficacy, but the sensitivity …
Currently, PD-L1 is the most widely useful biomarker to predict ICI efficacy, but the sensitivity …
Similar Efficacy Observed for First-Line Immunotherapy in Racial/Ethnic Minority Patients With Metastatic NSCLC
M Lee, J Liu, E Miao, S Wang, F Zhang, J Wei… - Journal of the National …, 2023 - jnccn.org
Background: Limited data exist on the impact of immunotherapy use in ethnic minority
patients with non–small cell lung cancer (NSCLC), because they have been …
patients with non–small cell lung cancer (NSCLC), because they have been …
Safety and Efficacy of Immune Checkpoint Inhibitors in Cancer Patients and Preexisting Autoimmune Disease: A Systematic Review and Meta-Analysis in Non–Small …
Background Cancer patients with preexisting autoimmune diseases (AID) have been
traditionally excluded from clinical trials of immune checkpoint inhibitors (ICI) due to …
traditionally excluded from clinical trials of immune checkpoint inhibitors (ICI) due to …
Real-world outcomes of Nivolumab, Pembrolizumab, and Atezolizumab treatment efficacy in Korean veterans with stage Iv non-small-cell lung cancer
A Ham, Y Lee, HS Kim, T Lim - Cancers, 2023 - mdpi.com
Simple Summary In clinical settings, patients receiving immune checkpoint inhibitors (ICIs)
have different treatment criteria than those enrolled in clinical trials. There are concerns …
have different treatment criteria than those enrolled in clinical trials. There are concerns …
Serum albumin and derived neutrophil-to-lymphocyte ratio are potential predictive biomarkers for immune checkpoint inhibitors in small cell lung cancer
Z Kuang, J Miao, X Zhang - Frontiers in Immunology, 2024 - frontiersin.org
Background Immune checkpoint inhibitors (ICIs) have reshaped the treatment landscape of
small cell lung cancer (SCLC), but only a minority of patients benefit from this therapy …
small cell lung cancer (SCLC), but only a minority of patients benefit from this therapy …
A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with …
H Abedian Kalkhoran, J Zwaveling, BN Storm… - BMC cancer, 2023 - Springer
Background This study was designed to investigate the impact of age on the effectiveness
and immune-related adverse events (irAEs) of programmed death-(ligand) 1 [PD-(L) 1] …
and immune-related adverse events (irAEs) of programmed death-(ligand) 1 [PD-(L) 1] …